Insider Transactions in Q4 2021 at Poseida Therapeutics, Inc. (PSTX)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 30
2021
|
Eric Ostertag Director |
SELL
Bona fide gift
|
Indirect |
48,902
-7.77%
|
-
|
|
Dec 30
2021
|
Eric Ostertag Director |
SELL
Bona fide gift
|
Direct |
93,955
-13.47%
|
-
|
|
Dec 21
2021
|
Johanna Mylet Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,716
+8.03%
|
$5,716
$1.55 P/Share
|
|
Dec 06
2021
|
Matthew A. Spear Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+13.99%
|
$10,000
$1.32 P/Share
|
|
Dec 06
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,828
+0.02%
|
$10,968
$6.9 P/Share
|
|
Dec 02
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
4,296
+0.04%
|
$25,776
$6.88 P/Share
|
|
Dec 01
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
18,365
+0.19%
|
$110,190
$6.85 P/Share
|
|
Nov 30
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
28,592
+0.3%
|
$171,552
$6.85 P/Share
|
|
Nov 29
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
11,057
+0.11%
|
$66,342
$6.89 P/Share
|
|
Nov 26
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
27,251
+0.28%
|
$163,506
$6.81 P/Share
|
|
Nov 24
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,054
+0.01%
|
$6,324
$6.89 P/Share
|
|
Nov 23
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
14,625
+0.15%
|
$87,750
$6.77 P/Share
|
|
Nov 19
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
11,104
+0.12%
|
$77,728
$7.44 P/Share
|
|
Nov 19
2021
|
Eric Ostertag Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+0.14%
|
$9,000
$9.15 P/Share
|
|
Nov 18
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
71,312
+0.74%
|
$499,184
$7.18 P/Share
|
|
Nov 17
2021
|
Kerry D. Ingalls Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$14,000
$7.0 P/Share
|
|
Nov 17
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
280,384
+2.87%
|
$1,962,688
$7.21 P/Share
|
|
Nov 16
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
27,680
+0.3%
|
$193,760
$7.17 P/Share
|
|
Nov 08
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
18,924
-0.27%
|
$132,468
$7.09 P/Share
|
|
Oct 11
2021
|
Eric Ostertag Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,525
+2.59%
|
$166,725
$9.15 P/Share
|
|
Oct 01
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
20,029
-0.28%
|
$140,203
$7.02 P/Share
|